Stock Price & Analysis

Hold HLN stock as analyst consensus remains positive with a Moderate Buy rating and a price target above current levels. However, consider the recent insider selling activity and market sentiment before making further decisions.

The price prediction for HLN stock in 2025 is expected to reach $12.50 per share. This forecast is supported by positive analyst ratings, with an average price target of p405.64, and Haleon's strategic share buyback program. However, the stock may face short-term volatility due to Pfizer's complete exit and negative insider sentiment.

The S1 support level for HLN Stock is $10 ,The R1 resistant level for HLN Stock is $10.37.

As of the end of day on 2025-04-02, the price of HLN Stock was $10.17.

The target price for HLN Stock according to analyst rating is 10.86, with the highest price target at 11.51 and the lowest at 10.20. Analysts have a Moderate Buy rating on HLN Stock overall.

The market cap of HLN is $92.0B.

Analysis and Insights

HLN appears overvalued based on several key metrics and recent developments:

1. High Valuation Metrics:

   • The P/E ratio of 24.55 is elevated compared to industry peers, suggesting investors are pricing in high growth expectations.
   • The EV/EBITDA ratio of 15.05 indicates a premium valuation relative to earnings.

2. Flattening Revenue Growth:

   • Quarterly revenue has shown inconsistent growth, with Q4 2024 revenue declining to £2.759B from £2.78B in Q3.
   • Net income also dropped sharply in Q4 to £231M, down from £485M in Q3, raising concerns about profitability consistency.

3. Negative Insider Sentiment:

   • Insiders have been selling shares at an increased pace, signaling potential lack of confidence in short-term prospects.

4. Pfizer's Stake Sale Impact:

   • Pfizer's sale of its entire 7.3% stake in HLN has introduced market uncertainty, potentially weighing on the stock price.

5. Analyst Consensus:

   • While analysts maintain a Moderate Buy rating, the average price target of £405.64 is below the current price, suggesting limited upside.

Conclusion

HLN's high valuation, inconsistent financial performance, and negative insider sentiment suggest the stock may be overvalued. Investors should exercise caution and consider waiting for a correction or clearer signs of growth stabilization before investing.

Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.

The price prediction for HLN stock in 2030 is approximately $44.00, driven by strong revenue growth projections of 4-6% and positive analyst sentiment with a Buy rating.

HLN has a total of 24622 employees.